

Literatur für onkologie heute 07/2021

SCHWERPUNKT: ASCO 2021

Therapiewandel bei Magen- und Ösophaguskarzinomen: Neue Daten und Studienupdates vom Amerikanischen Krebskongress (S. 22–30)

G. Stocker

1. Lordick F et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; 27: v50–v57
2. Moehler M et al. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs [S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL]. *Z Gastroenterol* 2019; 57: 1517–632
3. Smyth EC et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; 27: v38–v49
4. Chau I et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. *ASCO* 2021; abstr. #LBA4001
5. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma>, Zulassung Pembrolizumab PEC Ösophagus + AEG 1st. line mit Ctx. bei CPS \geq 10
6. Kato K et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. *ESMO* 2020; Abstr. #LBA8_PR
7. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-97_en.pdf
8. Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021, S0140-6736(21)00797-2
9. Kelly RJ et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med* 2021; 384: 1191–203
10. Shen L et al. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. *JCO* 2021; 39: 4012
11. Xu R-h et al. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). *JCO* 2021; 39: 4000
12. Kato K et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019; 20: 1506–17
13. Shah MA et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. *JAMA Oncol* 2019; 5: 546–50
14. Kojima T et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *J Clin Oncol* 2020; 38(35): 4138–48
15. Chin K et al. Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy. *JCO* 2021; 39: 204

16. Hartel N et al. Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial. *JCO* 2021; 39: 4029
 17. Kelly RJ et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. *JCO* 2021; 39: 4003
 18. Al-Batran SE, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019; 393(10184): 1948–57
 19. Reynolds JV et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). *JCO* 2021; 39: 4004
 20. Lorenzen S et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. *BMC Cancer* 2020; 20: 886
 21. Janjigian YY et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. *JCO* 2021; 39: 4013
 22. Shitara K et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. *N Engl J Med* 2020; 382: 2419–30
 23. Cella D et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. *JCO* 2021; 39: 4057
 24. Wainberg ZA et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). *JCO* 2021; 39: 160
 25. Catenacci DV et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). ASCO 2021, Clinical Science Symposium, Abstr. #4010
 26. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal>
 27. Moehler MH et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. *JCO* 2021; 39: 4002
 28. Wyrwicz L, Elimova E, Blum SI, et al. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. *JCO* 2021; 39: 4066
-

PHARMAFORUM:

Neue Immuntherapie: Checkpoint-Inhibitor für das fortgeschrittene oder rezidivierende Endometriumkarzinom (S. 76–77)

1. Makker V et al. *Gynecol Oncol Res Pract* 2017; 4: 19
2. Robert Koch-Institut (ed.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (ed.). In: *Krebs in Deutschland für 2015/2016*; 12: Berlin 2016
3. Colombo N et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. *Ann Oncol* 2016; 27(1): 16–41
4. Brooks RA et al. Current recommendations and recent progress in endometrial cancer. *CA Cancer* 2019; 69(4): 258–279
5. Colombo N et al. on behalf of the ESMO Guidelines Working Group. Endometrial Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *AnnOncol* 2013; 24(suppl 6): 33–38
6. Fachinformation Jemperli, Stand April 2021
7. Bonneville R et al. *JCO Precis Oncol* 2017; 2017: PO.17.00073
8. Alexandrov LB et al. *Nature* 2013; 500: 415–21
9. Howitt BE et al. *JAMA Oncology* 2015; 1: 1319–23
10. Luchini C et al. *Annals of Oncology* 2019; 30: 1232–1243
11. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. *Nat Rev Clin Oncol.* 2010; 7(3): 174–177
12. Umar A et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96(4): 261–268